• Filament Health’s patented, naturally derived psilocybin drug candidate PEX010 will be supplied to PSI-PARK, an investigator initiated randomized clinical trial evaluating psilocybin for the treatment of depression in Parkinson’s disease.

Toronto, Ontario–(Newsfile Corp. – August 14, 2026) – Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) (“Rhelion” or the “Company”) an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament Health Corp. (“Filament”), the Company develops, manufactures and supplies PEX010, its patented, standardized, GMP manufactured botanical psilocybin drug candidate, to clinical research and compassionate access programs at leading institutions worldwide.

The Company is pleased to announce that Filament has entered into a licence agreement with University Health Network (“UHN”) in Toronto for the supply of PEX010 to an investigator initiated clinical trial titled “Evaluating the Use of Psilocybin to Treat Parkinson’s Depression: A Randomized Clinical Trial” (“PSI-PARK”).

PSI-PARK is a randomized clinical trial evaluating psilocybin for the treatment of depression in people living with Parkinson’s disease. The study is sponsored by UHN and will be conducted by the principal investigator, Dr. Joshua Rosenblat, and researchers at UHN. Filament will supply PEX010 for use in the study as the investigational drug product. Note, Filament is not the sponsor of the trial and is not responsible for its conduct.

Depression affects a substantial proportion of people living with Parkinson’s disease and is among the strongest predictors of functional decline and reduced quality of life. It responds poorly to existing antidepressant treatment, and people with neurodegenerative disease have historically been excluded from psychedelic clinical research on safety grounds, leaving the therapeutic potential of psilocybin in this population largely unexamined. Depression in Parkinson’s disease therefore represents a significant unmet clinical need in an area where the scientific question remains genuinely open.

PSI-PARK adds to an emerging body of clinical research in this indication. In April 2025, results of an open label pilot study in people with mild to moderate Parkinson’s disease and mood dysfunction were published in Neuropsychopharmacology, reporting the first clinical data on psilocybin in any neurodegenerative disease. No serious adverse events were observed, and improvements in depression and anxiety measures were sustained to the final assessment. A larger randomized trial in the same indication is now underway.